Abstract Number: 2625 • 2013 ACR/ARHP Annual Meeting
Biologic Therapy In Refractory Uveitis Of Behcet’s Syndrome: Switching and Dose Modification. Multicenter Study Of 124 Patients
Background/Purpose: Several situations can be observed in patients undergoing biologic therapy in uveitis associated to Behçet´s syndrome (BS): a) Patients are switched to another therapy…Abstract Number: 2627 • 2013 ACR/ARHP Annual Meeting
Prognostic Factors Of Visual Function In The Treatment With Infliximab For Uveitis Of Behçet’s Disease
Background/Purpose: Infliximab, a chimeric monoclonal antibody against TNF-a, is expected to improve prognosis of visual function in patients with severe and refractory uveitis of Behçet's…Abstract Number: 2628 • 2013 ACR/ARHP Annual Meeting
Immunogenicity Of Infliximab Modulates Efficacy and Safety In Behcet’s Disease Patients With Uveitis
Background/Purpose: Infliximab (IFX) suppresses ocular attacks in Behcet’s disease (BD) with uveitis, resulting in favorable long-term visual prognosis. However, some patients had ocular attacks which…Abstract Number: 2629 • 2013 ACR/ARHP Annual Meeting
Is Complete Remission a Realistic Target With Current Therapeutic Options in Behçet’s Disease ?
Background/Purpose: The clinical course of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing nature is unsufficiently explored. As complete remission should be aimed…Abstract Number: 2631 • 2013 ACR/ARHP Annual Meeting
Fertility In Behçet’s Syndrome: Structured Interview In A Multidisciplinary Center
Background/Purpose: Behçet’s Syndrome (BS) follows an active course during the child-bearing years in both men and women. Whether fertility is decreased among the BS patients…Abstract Number: 2632 • 2013 ACR/ARHP Annual Meeting
Long Term Outcome Of Neuro-Behçet’s Disease
Background/Purpose: Neurological involvement occurs in 5.3 to up to 59% of patients with Behçet’s disease (BD). Although the clinical and imaging features of neuro-Behçet’s disease…Abstract Number: 2613 • 2013 ACR/ARHP Annual Meeting
NF-κB Pathway Is Depleted In Phagocytes From Behçet´s Disease Patients Secondarily To Constitutive Phosphorylation Of The p65 Subunit
Background/Purpose: : Increased neutrophil activation has been previously shown in Behçet’s disease (BD) patients and it is unclear whether neutrophil activation occurs constitutively or if…Abstract Number: 2385 • 2012 ACR/ARHP Annual Meeting
Prognostic Impact of HLA-B*51 and HLA–A*26:01 On Ocular Behcet’s Disease
Background/Purpose: To investigate the prognostic implication of HLA-B*51 and HLA-A*26:01on visual outcome in Korean Behcet’s disease (BD) patients with uveitis. Methods: Seventy-seven Korean BD patients…Abstract Number: 186 • 2012 ACR/ARHP Annual Meeting
Long-Term Infliximab Therapy in Patients with Behcet’s Disease Is Well Tolerated without Increasing Risk of Serious Infections
Background/Purpose: Infliximab (IFX) is a monoclonal antibody against tumor necrosis factor-a (TNF-a) and is increasingly used in various immune-related diseases including rheumatoid arthritis (RA), ankylosing…Abstract Number: 2394 • 2012 ACR/ARHP Annual Meeting
Fibromyalgia in Behçet’s Disease Is Associated with Disease Activity
Background/Purpose: Studies on the relationship between Fibromyalgia (FM), a generalized pain disorder with up to 2% prevelance and Behcet’s Disease (BD), a systemic, inflammatory vasculitis,…Abstract Number: 2369 • 2012 ACR/ARHP Annual Meeting
Aspects of Innate Immunity in Behçet´s Disease: A Model of Autoinflammatory Disease?
Background/Purpose: Behçet's disease (BD) is a systemic vasculitis of unknown etiopathogenesis. Increased neutrophil activation has been previously shown in BD patients and it is unclear…Abstract Number: 2370 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide DNA Methylation Study Identifies Significant Epigenetic Changes Across the Genome and in Multiple HLA Loci in Behcet’s Disease
Background/Purpose: Behcet’s disease (BD) is a systemic vasculitis of poorly understood etiology. Herein, we study the DNA methylome in BD for the first time and…Abstract Number: 2371 • 2012 ACR/ARHP Annual Meeting
The Unmet Need in Behcet’s Disease: Most Patients Are Not in Complete Remission in the Long-Term Follow-up
Background/Purpose: The nature of Behcet’s disease (BD) as a multi-systemic disorder with a remitting-relapsing course is unsufficiently explored. As complete remission should be aimed in…Abstract Number: 2372 • 2012 ACR/ARHP Annual Meeting
Efficacy of Quantitative Analysis of Brainstem Atrophy On Magnetic Resonance Imaging for Diagnosis of Chronic Progressive Neuro-Behçet’s Disease
Background/Purpose : CNS involvement in Behçet's disease, usually called neuro-Behçet's disease (NB), can be classified into acute NB (ANB) and chronic progressive NB (CPNB) based…Abstract Number: 2373 • 2012 ACR/ARHP Annual Meeting
The Clinical Course of the Acute Deep Vein Thrombosis of the Legs in Behçet’s Syndrome
Background/Purpose: 15-50% of patients with Behçet’s syndrome have vascular involvement (BS). Deep vein thrombosis is the most common form with lower extremity deep vein thrombosis…
ACR Meeting Abstracts